C.G. Gillooly

C.G. Gillooly

Chief Executive Officer

Mr. Gillooly has over 30 years of experience leading teams, executing acquisitions and partnerships, and creating enterprise value across multiple industries including healthcare, life sciences, MedTech, manufacturing, and consulting. He has proven himself to be an exceptional recruiter and leader of high performing teams.

After earning degrees in Business from St. Louis University and an MBA from Duke University, Mr. Gillooly joined Cooper Industries (now Eaton Corporation) initially as a financial analyst and then becoming the youngest General Manager and Brand Manager of four subsidiaries. He pioneered the use of data and analytics to rationalize product portfolios and adjust pricing strategies to enhance margins and gain share in very competitive markets.  

After Cooper, Mr. Gillooly joined BuildNet, a venture-backed technology company acquiring software platforms aimed at improving efficiencies in the construction market. Mr. Gillooly negotiated the acquisition of 11 software companies in less than a year to form the basis for that platform and BuildNet rose to a multi-billion dollar valuation. Leveraging his knowledge of the space, Mr. Gillooly joined BuildLinks, a venture backed early-stage software company as CEO. He led the company through successive funding rounds, building out the team and releasing the first commercial product.  

Mr. Gillooly’s track record of assembling high performing teams and generating inorganic growth brought him to Quintiles (now IQVIA) and their investment arm NovaQuest. There, Mr. Gillooly recruited a global team of executives to work directly with venture capital and private equity firms and their portfolio companies to accelerate drug development in emerging life science companies. His team exceeded their business goals every year for nine years, growing to almost $500m in bookings and closing more than 30 direct equity investments. These successes became the foundation for what is now IQVIA Biotech.

After Quintiles’ IPO and merger, Mr. Gillooly was recruited to become the CEO of Lumagenics, a MedTech startup with technology to combat hospital acquired infections (HAI’s.) In less than 18 months, he grew the company’s employee base, developed a comprehensive IP portfolio strategy, negotiated a development partnership with Ximedica (now Veranex) completed over 300 independent laboratory tests confirming efficacy, delivered a scientific white paper to the global infection control conference, and secured 3 rounds of private equity funding.  

Throughout his career, Mr. Gillooly has proven to be an authentic leader, coaching and inspiring his teams to excel in delivering client value and generating commercial success. He is a confident public speaker having presented to Boards, Conferences, and other large groups. He has deep experience in negotiating M+A transactions as well as strategic partnerships. 

In his spare time, Mr. Gillooly enjoys the privilege of playing some of the most historic golf courses in the world despite his marginal abilities! Following multiple knee surgeries, he has “retired” from competitive basketball and now focuses on wake surfing and standup paddle boarding.

Quote

“Our deep expertise and vast experience give us the insights into the needs and requirements of our clients and industry standards.”